MedTrace Logo

The Effect of Intranasal Insulin on Motor and Non-motor Symptoms in Parkinson's Disease Patients

NCT04687878 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-04-23

No results posted yet for this study

Summary

This study will evaluate the effect of intranasal insulin on motor and non-motor symptoms of patients with Parkinson's disease over a 12-week period.

Conditions

  • Parkinson Disease

Interventions

DRUG

Insulin

20 IU twice a day, intranasally, every day for 12 weeks

DRUG

Normal saline

twice a day, intranasally, every day for 12 weeks

Sponsors & Collaborators

  • dr.dargahi

    lead OTHER

Principal Investigators

  • Leila Dargahi, PharmD/PhD · Shahid Beheshti University of Medical Sciences

  • Mehri Salari, MDFellowship · Shahid Beheshti University of Medical Sciences

  • Abolhassan Ahmadiani, PharmD/PhD · Shahid Beheshti University of Medical Sciences

  • Neda Valian, PhD · Shahid Beheshti University of Medical Sciences

  • Leila Mohaghegh Shalmani, PharmD/PhD · Shahid Beheshti University of Medical Sciences

  • Helia Ashourizadeh, Intern · Shahid Beheshti University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2022-06-20
Completion
2023-09-20

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04687878 on ClinicalTrials.gov